2.MSC paradox: While engineered MSCs offer promise as tumor-homing drug carriers (e.g., IDD-1040-paclitaxel complexes) and immunomodulators, their capacity to differentiate into cancer-associated fibroblasts (CAFs) via TGF-β secretion exacerbates tumor progression. Here, TGFB1 is linked to neoplasm.